IDENIX PHARMACEUTICALS INC |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| 2015 | AbbVie : Merck says hepatitis C drugs to lose breakthrough status | RE |
| 2014 | Apple : Wall St. edges up, lifted by mergers, acquisitions | RE |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Teresa Dahlman
IRC | Investor Relations Contact | - | - |
Michele Liuzzi
PRN | Corporate Officer/Principal | - | - |
Adel Moussa
PRN | Corporate Officer/Principal | - | 02-02-28 |
John Mao
PRN | Corporate Officer/Principal | - | - |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 1 | 151,503,782 | 117,733,252 ( 77.71 %) | 0 | 77.71 % |
Company contact information
Sector
| 1st Jan change | Capi. | |
|---|---|---|
| -2.86% | 87.37B | |
| +3.95% | 41.01B | |
| -21.94% | 28.08B | |
| +53.11% | 24.72B | |
| -5.41% | 17.47B | |
| -44.23% | 11.69B | |
| -17.60% | 11.6B | |
| -13.96% | 11.56B | |
| -0.22% | 8.44B |
- Stock Market
- Equities
- Stock
- Company Idenix Pharmaceuticals Inc
